JanOne logo

JanOneNASDAQ: JAN

Profile

Country:

United States

IPO:

07 November 1991

Next earnings report:

15 August 2024

Last dividends:

N/A

Next dividends:

N/A
$19.38 M
-54%vs. 3y high
12%vs. sector
-vs. 3y high
-vs. sector
-54%vs. 3y high
81%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Fri, 28 Jun 2024 20:00:17 GMT
$2.14+$0.01(+0.47%)

Dividend

No data over the past 3 years

Analysts recommendations

Institutional Ownership

JAN Latest News

JanOne Appoints Vay Tham as its Chief Revenue Officer and President of its Fintech Subsidiary, ALT5 Sigma
prnewswire.com26 June 2024 Sentiment: -

LAS VEGAS , June 26, 2024 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a multidisciplinary organization with a focus on healthcare and fintech, is pleased to announce that it has appointed Mr. Vay Tham as its Chief Revenue Officer and President of ALT5 Sigma, Inc., its wholly-owned subsidiary.

JanOne's Subsidiary, Alt5, Reports 91% year over year increase in Transaction Volume to US $289 million for April and May 2024
prnewswire.com13 June 2024 Sentiment: -

LAS VEGAS , June 13, 2024 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a multidisciplinary organization with a focus on healthcare and fintech, released today its wholly-owned subsidiary, ALT5 Sigma, transaction volume for April and May 2024. According to the Company, ALT5 Sigma transaction volume reached US$289 million for the months of April and May 2024 combined, compared to US$151 million in transaction volume for the months of April and May 2023 combined, representing a year-over-year increase of 91%.

JanOne Inc. added to the Russell Microcap® Index
prnewswire.com03 June 2024 Sentiment: POSITIVE

LAS VEGAS , June 3, 2024 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a multidisciplinary organization with a focus on healthcare and fintech, announced today that it has been added to the Russell Microcap® Index. The Russell Microcap® Index was launched on June 1, 2005 and measures the performance of the microcap segment of the US Equity market and consists of 1,000 securities, including Virgin Galactic HLDG, Skye Bioscience, Bitcoin Depot Inc., Core Scientific, Hut 8 Corp., and Sonder Holdings Inc., to name a few.

JanOne to Present at the Dawson James 8th Annual Investment Conference
PRNewsWire21 September 2023 Sentiment: POSITIVE

Chief Medical Officer Dr. Amol Soin will explain innovative approaches to pain management and JanOne's development of non-addicting treatments for pain LAS VEGAS , Sept. 21, 2023 /PRNewswire/ -- JanOne (Nasdaq: JAN), the biopharmaceutical company focused on developing non-addicting painkillers and novel treatments for the causes of pain, will participate in investor sessions at the Dawson James Securities 8th Annual Investment Conference in Jupiter, Florida.

JanOne to Present In Person and by Video at H.C. Wainwright's 25th Annual Global Investment Conference
PRNewsWire31 August 2023 Sentiment: POSITIVE

Chief Medical Officer Dr. Amol Soin will discuss innovative approaches to pain management and JanOne's development of non-addicting treatments for pain LAS VEGAS , Aug. 31, 2023 /PRNewswire/ -- JanOne (Nasdaq: JAN), the biopharmaceutical company focused on developing non-addicting painkillers and novel treatments for the causes of pain, will participate in investor sessions at the H.C. Wainwright 25 th  Annual Global Investment Conference in New York City.

JanOne to Present Prior Phase II Data on Diabetic Neuropathy at the Ohio Society of Interventional Pain Physicians Annual Meeting
PRNewsWire18 August 2023 Sentiment: POSITIVE

JAN101 Showed Statistically Significant Reduction in Pain and Improvement in Nerve Conduction Velocity in Prior Phase II study. LAS VEGAS , Aug. 18, 2023 /PRNewswire/ -- JanOne (Nasdaq: JAN), a biopharmaceutical company specializing in developing non-addicting pain killers and treatments for underlying causes of pain, will present prior data on Jan101's randomized double blind placebo-controlled trial in diabetic neuropathy patients.

What type of business is JanOne?

JanOne Inc., a clinical-stage biopharmaceutical company, focuses on identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the unmet medical need for the treatment of pain and addiction. It operates through three segments: Biotechnology, Recycling, and Technology. The company's lead product candidate is JAN101, a patented oral and sustained release pharmaceutical composition of sodium nitrite that targets poor blood flow to the extremities in patients with diabetes or peripheral artery disease to treat pain. It also provides turnkey appliance recycling and replacement services for utilities and other sponsors of energy efficiency programs; and designs, develops, and sells cellular transceiver modules and associated wireless services. The company was formerly known as Appliance Recycling Centers of America, Inc. and changed its name to JanOne Inc. in September 2019. JanOne Inc. was founded in 1976 and is headquartered in Las Vegas, Nevada.

What sector is JanOne in?

JanOne is in the Industrials sector

What industry is JanOne in?

JanOne is in the Waste Management industry

What country is JanOne from?

JanOne is headquartered in United States

When did JanOne go public?

JanOne initial public offering (IPO) was on 07 November 1991

What is JanOne website?

https://www.janone.com

Is JanOne in the S&P 500?

No, JanOne is not included in the S&P 500 index

Is JanOne in the NASDAQ 100?

No, JanOne is not included in the NASDAQ 100 index

Is JanOne in the Dow Jones?

No, JanOne is not included in the Dow Jones index

When does JanOne report earnings?

The next expected earnings date for JanOne is 15 August 2024